Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Lexicon Pharmaceuticals Inc. (LXRX)

4.04   -0.2 (-4.72%) 01-17 16:00
Open: 4.26 Pre. Close: 4.24
High: 4.3 Low: 3.99
Volume: 912,492 Market Cap: 429M
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.305 - 4.332 4.332 - 4.351
Low: 3.929 - 3.961 3.961 - 3.984
Close: 3.998 - 4.045 4.045 - 4.078

Technical analysis

as of: 2020-01-17 4:37:57 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 5.53     One year: 6.20
Support: Support1: 3.81    Support2: 3.17
Resistance: Resistance1: 4.74    Resistance2: 5.31
Pivot: 4.11
Moving Average: MA(5): 4.20     MA(20): 4.16
MA(100): 3.52     MA(250): 4.57
MACD: MACD(12,26): -0.01     Signal(9):
Stochastic oscillator: %K(14,3): 58.33     %D(3): 62.92
RSI: RSI(14): 45.97
52-week: High: 8.39  Low: 1.13  Change(%): -29.7
Average Vol(K): 3-Month: 139874  10-Days: 81675

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
LXRX has closed above bottom band by 34.4%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to LXRX's normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC
The company has announced it has completed the safety of an initial run-in cohort of its TELE-ABC Phase 2 clinical study. The post Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC appeared first on Investing News Network .

Why Lexicon Pharma Shares Are Moving Lower
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. Lexicon was co-developing the pipeline asset with Sanofi SA (NASDAQ: SNY ) but has terminated the alliance effective Sept. 9. FDA Firm On Rejection Decision The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for … Full story available on

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 106.27
Shares Float (M) 40.63
% Held by Insiders 0.98
% Held by Institutions 97.25
Shares Short (K) 12940
Shares Short P. Month (K)

Stock Financials

EPS 1.475
Book Value (p.s.) 1.550
PEG Ratio 0.08
Profit Margin 49.78
Operating Margin 62.02
Return on Assets (ttm) 33.9
Return on Equity (ttm) 243.1
Qtrly Rev. Growth 4126.9
Gross Profit (p.s.) -0.372
Sales Per Share
EBITDA (p.s.) 1.946
Qtrly Earnings Growth
Operating Cash Flow (M) 111.05
Levered Free Cash Flow (M) 43.08

Stock Valuations

P/E 2.74
P/E Growth Ratio -0.05
P/BV 2.61
P/S 1.29
P/CF 3.87

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2015-05-21
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.